Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

STCube Pharmaceuticals at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

STCube Pharmaceuticals brings 3 presentations to SITC 2026 in Phoenix. Its program centres on nelmastobart, an antibody against BTN1A1, from safety studies to combination treatment. It reports clinical outcomes and spatial tissue profiling when nelmastobart is added to trifluridine/tipiracil and bevacizumab in colorectal cancer that has stopped responding.

Organization	SITC 2026 Attendance
SP STCube Pharmaceuticals Seoul, South Korea
	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Restricted normal-tissue expression of BTN1A1 and a favorable developmental safety profile of nelmastobart support a broad therapeutic window Exhibition Halls 4-6 · Poster 983 New agents · Regulatory Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Targeting BTN1A1 with nelmastobart enhances osimertinib efficacy in EGFR-mutant NSCLC organoid and zebrafish xenograft models Exhibition Halls 4-6 · Poster 625 New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Spatial profiling and clinical outcomes of nelmastobart, a first-in-class anti-BTN1A1 antibody, with trifluridine/tipiracil and bevacizumab in refractory colorectal cancer (STCUBE-003) Exhibition Halls 4-6 · Poster 520 New agents · Clinical

Organization

SITC 2026 Attendance

STCube Pharmaceuticals

Seoul, South Korea

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Restricted normal-tissue expression of BTN1A1 and a favorable developmental safety profile of nelmastobart support a broad therapeutic window

Exhibition Halls 4-6 · Poster 983

New agents · Regulatory

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Targeting BTN1A1 with nelmastobart enhances osimertinib efficacy in EGFR-mutant NSCLC organoid and zebrafish xenograft models